华法林在患有无症状门静脉血栓的肝硬化患者中的比较有效性:一个多中心,随机对照试验
Shenxin Lu1,2,3, Jie Chen1,4,5, Rui Zhang1,4
1Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
Expert review of gastroenterology & hepatology
|January 18, 2024
概括
华法林在肝硬化患者中有效治疗无症状门静脉血栓 (PVT),提高了再通道化率. 这种抗凝血药物治疗是安全的,没有显著增加出血或死亡率,并减少了炎的恶化.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
- 血栓形成研究研究
背景情况:
- 肝硬化患者的非症状门静脉血栓 (PVT) 存在不清楚的治疗风险和益处.
- 抗凝剂治疗在这种特定患者群体中的作用需要进一步研究.
研究的目的:
- 评估华法林治疗肝硬化患者无症状PVT的有效性和安全性.
- 评估再通道化率,出血事件,死亡率和炎恶化.
主要方法:
- 一个多中心,Zelen设计的随机对照试验.
- 64名没有症状的PVT肝硬化患者被随机 (1:1) 分给华法林或不接受治疗.
- 一年的随访期. 一年的随访期.
主要成果:
- 华法林组的再通道化概率显著更高 (71.9%与34.4%,p=0.004 ITT; 76.7%与32.4%,p<0.001 PP).
- 华法林治疗是重新道化的独立预测因子 (HR 2.776).
- 在出血事件或死亡率上没有显著差异;华法林组的下炎恶化 (3.3%对26.5%,p=0.015).
结论:
- 华法林是一种有效且安全的抗凝治疗,用于肝硬化患者的非症状PVT.
- 治疗导致改善再通道化和减少炎恶化,而不会增加不良事件.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
701
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
Esophageal Varices-II: Clinical Features and Management
69
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
69
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
525
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525
Therapeutic Index
4.3K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.3K
Hepatic Drug Clearance: Effect of Protein Binding
200
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
200


